Morgan Stanley raised the price target for the Bausch + Lomb Corp (NYSE:BLCO) stock from “an Equal-weight” to “an Overweight”. The rating was released on May 06, 2024, according to finviz. We ...

BLCO stock results show that Bausch & Lomb met analyst estimates for earnings per share but missed on revenue for the first ...

According to the FDA, Palmer Candy was warned by its supplier that it uses for the liquid coating on its white-coated items ...

Bausch + Lomb Corporation (NYSE:BLCO) Q1 2024 Earnings Call Transcript May 1, 2024 Bausch + Lomb Corporation misses on earnings expectations. Reported EPS is $0.07 EPS, expectations were $0.09.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(NEXSTAR) — Pharmaceutical company Bausch + Lomb is recalling about 32,000 units of its Project Watson Eyelid Wipes for dogs ...

In today's trading, Bausch Lomb Corporation shares opened at $20.83 and closed at $19.92. prices ranged from a low of $19.92 to a high of $20.83. Shares dipped -4.05% from the previous day's close of ...

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) today announced the results of its 2024 annual meeting of shareholders.

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...